CAR-T cell therapy for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have recurrent glioblastoma (a type of brain tumor that has come back) confirmed by a biopsy or previous treatment.
- You are able to do daily activities with minimal help (score of 50 or more on the Karnofsky scale).
- Your life expectancy is at least 12 weeks.
- You are not pregnant and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new CAR-T cell therapy for people recently diagnosed with glioblastoma, a type of brain cancer. It uses the patient's own immune cells, modified to target markers on the tumor. The goal is to see if this treatment can help control the cancer after surgery and before standard therapies like radiation or chemotherapy.
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Hear when a new Recurrent Glioblastoma Multiforme (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.